Editor In Chief, Pharma Insights Europe
Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
23+ years of experience
Eleanor joined Pharma Intelligence in 2000 as companies reporter on Scrip, and has held a number of editorial roles on Pharma Intelligence's pharma and medtech publications. She has interviewed countless industry leaders and specialists, explored business developments and strategy, pipeline trends, policy and regulatory stories, delved into M&A, licensing, partnerships, financing, financial reports, clinical trial updates, market trends and more.
Based in London, she regularly appears on conference panels and in the media to discuss matters relating to the biopharma industry. She has an MA in modern languages from the University of Edinburgh and previously worked as a translator of European business news for the Financial Times.
By Eleanor Malone 20 Oct 2022
Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.
By Eleanor Malone 01 Apr 2020
News from around the biopharma sector and its efforts to meet the challenges posed by the coronavirus pandemic.
By Eleanor Malone 26 Mar 2020
Regeneron's head of R&D George Yancopoulos delivers some stirring words about the need to unify against the global threat posed by COVID-19.
By Eleanor Malone 11 Sep 2019
AstraZeneca’s head of R&D spoke to Scrip about the outstanding results for dapagliflozin in heart failure regardless of diabetes status.
Topic Company Analysis Diabetes
By Eleanor Malone 02 Jul 2019
Navigating the issues presented by biosimilars is becoming more complicated. With new barriers facing biosimilar originator companies and threatening to derail development, knowing how to formulate and manage your own biosimilar action plan is critically important.
By Eleanor Malone 26 Jun 2019
Peter Martin, COO of Norgine, is concerned about the ‘mood music’ in the political environment in the UK, and warns about the risks of the UK leaving the EU without a deal in place.
Topic Brexit Business Strategies
By Eleanor Malone 10 Jan 2019
Scrip journalists asked industry executives, consultants and analysts what they believe the big themes, trends and events will be in 2019. Here's what they told us about advances in therapeutic technologies and areas of clinical innovation.
Topic Research & Development Business Strategies BioPharmaceutical
By Eleanor Malone 21 Jun 2018
Emerging Company Profile: ENYO Pharma has been around for barely four years, but it is already advancing its lead programs into Phase II trials in hepatitis B and NASH, and anticipates many more uses for its virology-based platform that will go way beyond treating virus infections.
Topic Company Analysis Hepatitis B
By Eleanor Malone 31 May 2018
Peter Guenter has steadied the ship at Almirall, and after seven months in the role he outlines his vision for the company in his first exclusive interview as CEO of Spain's largest pharma company.
By Eleanor Malone 15 May 2018
LifeSci Advisors has thrown its back into getting more women on boards, and its efforts have been praised. However, with just 13 women placed in a year and a half, the task is not an easy one.
By Eleanor Malone 05 Jan 2018
Scrip has gleaned from experts and industry executives their expectations and predictions for 2018's hot topics.
By Eleanor Malone 20 Dec 2017
Forge Therapeutics is aiming to have developed a novel class of antibiotic to treat Gram-negative superbugs.
Topic Infectious Diseases
By Eleanor Malone 14 Nov 2017
Emerging Company Profile: Finland's Forendo Pharma hopes an imminent improvement in diagnostic possibilities will eventually help it commercialize a drug for endometriosis.
By Eleanor Malone 31 Jul 2017
Pascal Soriot stands by the ambitious growth target he set for AstraZeneca in his defense against Pfizer's 2014 bid for the company. Any shortfall in the target of $45bn by 2023 will reflect the weakening of the dollar rather than product challenges for the UK company, the bullish CEO told Scrip one day after the company delivered disappointing Phase III data that slashed around 15% from its share price.
Topic Company Analysis
By Eleanor Malone 12 Dec 2016
Delivering clinical advances in areas including immuno-oncology and Alzheimer's disease data while navigating the stormy seas of global politics could represent an opportunity for pharma to influence change. An uptick in sector M&A could also ensue if Trump offers US corporations a tax holiday.
28 Jun 2022
30 Mar 2022
16 Mar 2022
10 Mar 2022
01 Mar 2022
17 Feb 2022
18 Oct 2021
22 Jun 2021
14 Jun 2021
20 Sep 2017
19 Sep 2017
18 Jul 2017
11 Jul 2017
31 Mar 2016
30 Mar 2016